Phase II trial of 6-thioguanine administered as 120 hour continuous infusion for refractory or recurrent small cell lung cancer. A Southwest Oncology Group study.
Nineteen eligible patients with recurrent small cell lung cancer were treated with a 120 hour continuous infusion of 6-thioguanine at a starting dose of 35 mg/m2/day. There were no responses in these 19 patients. Toxicity was acceptable with the primary toxicity being hematologic. Based on this trial, 6-thioguanine is not felt to have significant antitumor activity in this patient population.
University of Kansas Medical Center, Kansas City.
S K
SK
Williamson
J
J
Crowley
R B
RB
Livingston
G
G
Weiss
D000368:Aged; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D015507:Drugs, Investigational / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D011379:Prognosis; D013866:Thioguanine / Q000008:administration & dosage* / Q000009:adverse effects; D013997:Time Factors
D015507:Drugs, Investigational; D013866:Thioguanine